Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

ConditionsHeart Transplant Rejection Immune Suppression Pediatric Heart Transplant Medication Nonadherence Health Behavior Remote Monitoring Patient Engagement

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age10-21

SponsorUniversity of Florida

About this trial

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

Eligibility criteria

Qualifiers

Eligible participants are 10-21 years of age

Have received a heart transplant and are followed participating pediatric heart transplant centers

English-speaking or Spanish-speaking

Own a smart-phone or have access to the mobile app through other devices

Disqualifiers

None

Trial design

Treatments tested in this trial

DOT intervention

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University of Florida

Lead sponsor

emocha Mobile Health, Inc.

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Source ClinicalTrials.gov